← Leaderboards
Srdan Verstovsek
University Of Tx Md Anderson Can Ctr
$1,168,238
Attributed
$2,336,476
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $475.9K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,336,476 · 1
By mechanism
R01$2,336,476 · 1
Top collaborators
- Kapil N. Bhalla5 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Kapil N. Bhalla$16,921,043
- Michael Richard Green$8,960,138
- Steven Grant$1,384,176
- Marina Y Konopleva$11,210,192
- Blaine Bartholomew$12,587,770
Others in their field
Other Emerging Leaders on “Cyclin-Dependent Kinases”
- Tamer M A Mohamed · Baylor College Of Medicine$3,187,572
- Alexandra Margaret Lynn Binder · University Of California Los Angeles$3,091,560
- David R Raleigh · University Of California, San Francisco$2,733,596
- John Kent Werner · Cogentis Therapeutics, Inc.$2,210,678
- Barbara Burtness · Yale University$2,049,548
- Xinghui Sun · University Of Nebraska Lincoln$1,955,473
Research focus
Cyclin-Dependent KinasesDependenceChromatin Remodeling FactorC-TerminalAttenuatedCyclin T1ApoptoticBcl2 GeneAtac-SeqBindingBinding SitesBromodomainC-Myc GenesCalreticulinCatalytic DomainCdk9 Protein KinaseCell Culture TechniquesCell GrowthCell LineCell SurvivalChemotherapyChip-SeqChromatinDisease Progression
Grant awards (5)
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML$452,068
R01 · FY2024 · CA
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML$466,344
R01 · FY2023 · CA
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML$466,344
R01 · FY2022 · CA
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML$475,860
R01 · FY2021 · CA
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML$475,860
R01 · FY2020 · CA